(Q43171541)

English

A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

scientific article published on 30 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

author name string

Eisaku Iwanaga

1

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Tomoko Nanri

2

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Naofumi Matsuno

3

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Toshiro Kawakita

4

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Hiroaki Mitsuya

5

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Norio Asou

6

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 January 2009

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

94

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

433-435

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Jak2: normal function and role in hematopoietic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

25 May 2018

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

25 May 2018

The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

25 May 2018

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

15 August 2018

The JAK2 V617F mutation in de novo acute myelogenous leukemias.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

15 August 2018

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

15 August 2018

Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649368

1 December 2018

JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19181784

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19181784

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML

1 reference

https://pubmed.ncbi.nlm.nih.gov/19181784

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/19181784

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status

1 reference

https://pubmed.ncbi.nlm.nih.gov/19181784

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.13283

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43171541&oldid=1982833998"